【Expo 2025 Osaka, Kansai, Japan】 AI Medical Service to Exhibit at “Next-Generation Medical Equipment Experience Corner”

AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has been selected to exhibit at the “Next-Generation Medical Devices and Equipment Experience Corner.” The exhibition is part of the “HEALTH DESIGN Live Brighter” event hosted by JETRO in conjunction with the “Health and Well-being Week” of Expo 2025 held in Osaka, Japan.

About the Next-Generation Medical Devices and Equipment Experience Corner 

The “Next-Generation Medical Devices and Equipment Experience Corner” is an interactive exhibition designed to offer the public hands-on experience with cutting-edge devices. Its goal is to raise awareness of Japan's advanced medical and welfare technologies. A total of 13 Japanese companies will participate, including 7 from the medical sector and 6 from the welfare sector. Visitors to the medical-related booths will experience demos of the latest devices used in healthcare like surgical assistance robots and AI-powered diagnostic imaging software. Visitors to the welfare-related booths can try out devices with the latest consumer technology like wearable ultrasound devices.

Overview of the “Next-Generation Medical Devices and Equipment Experience Corner”

About Endoscopic AI

AIM’s endoscopic AI analyzes images acquired with endoscopic equipment and detects areas of suspected adenoma and early gastric cancer in the images before helping the examiner identify these lesions by placing a frame within the image and playing a sound alert. These AI functions help the observer interpret the image and detect lesions.

Image of endoscopic AI

  About AIM’s Exhibit

Visitors have the opportunity to watch a demo video of AI analyzing endoscopic images during an endoscopic exam. Detecting early gastric cancer can be challenging, with studies suggesting that 4.5% to 25.8% of cases may be undetected[1]. We encourage everyone to visit the exhibit and gain firsthand understanding of the cutting-edge technology that is expected to play a significant role in future healthcare, as well as gain insight into the difficulties of making accurate diagnoses.

Statement from Tomohiro Tada, CEO and Medical Doctor

We are deeply honored to have been selected as an exhibitor for the "Next-Generation Medical Devices and Equipment Experience Corner" at the JETRO-hosted event "HEALTH DESIGN: Live Brighter," a part of Expo 2025's "Health and Well-being Week."

Founded in 2017, our company is a startup focused on developing endoscopic AI, with the goal of becoming a global leader in this specialized field. In 2024, we launched software designed to assist in the detection of epithelial tumors, including adenomas and early gastric cancer lesions limited to the mucosal or submucosal layers of the stomach. We are committed to using Japan’s advanced endoscopic AI to save lives around the world and will continue to work tirelessly towards this mission. We greatly appreciate your ongoing guidance and support.

About AI Medical Service Inc.

AI Medical Service (AIM) is a Tokyo-based med-tech company and healthcare startup, founded by a practicing endoscopist, dedicated to the research and development of endoscopic AI. In 2018, AIM became the first in the world to develop and publish AI technology for detecting gastric cancer, positioning ourselves at the forefront of endoscopic AI research. In December 2023, AIM received approval to manufacture and sell our first AI product, an endoscopic image diagnostic support software, and later launched sales of said product in March 2024. Having collaborated on joint research with over 140 institutions worldwide, we are expanding our business with the mission of “Save Lives All Over the World.”

Tomohiro TADA, M.D., Ph.D., FJGES

CEO, AI Medical Service Inc.

Chairman Emeritus, J's CLINIC of Gastrointestinal Endoscopy & Proctology

Dr. Tomohiro TADA is the CEO of AI Medical Service Inc.; the founder of Tada Tomohiro The Institute of Gastroenterology & Proctology; and Visiting Lecturer, Department of Surgical Oncology, Graduate School of Medicine, The University of Hospital.

Dr. TADA received his M.D. of from The University of Tokyo School of Medicine in 1996 and Ph.D. from The University of Tokyo Graduate School of Medicine (Department of Surgical Oncology) in 2005 . He trained in colorectal surgery at The University of Tokyo Hospital.